The Twenty-Second International Conference on Antiviral Research

Sponsored by

The International Society For Antiviral Research

Miami Beach Resort & Spa

Miami Beach, Florida, USA

May 3–7, 2009

Table of Contents
	Page
Organization and Conference Committees
Organizing Secretariats, The International Society for Antiviral Research
Corporate Sponsors
Keynote Address, Social Functions
Scientific Program
Sunday, May 3, 2009
Drug Discovery and Development 101
Keynote Address
Monday, May 4, 2009
Oral Session 1: Mini-Symposium: Development of Novel Therapies for Hepatitis C Virus (HCV): Continuing the Fight
Oral Session 2: Hepatitis Viruses
Poster Session 1: Retroviruses, Hepatitis Viruses, Respiratory Viruses, Emerging Viruses, and Antiviral Methods
Tuesday, May 5, 2009
Oral Session 3: Retroviruses
Clinical Symposium
Poster Session 2: Herpesviruses, Topical Microbicides, Poxviruses, Other Antiviral Agents, Medicinal Chemistry, and Animal Models
Wednesday, May 6, 2009
Oral Session 4: Herpesviruses and Poxviruses
Invitation to 23rd ICAR, ISAR Business Meeting
Oral Session 5: Respiratory Viruses, Emerging Viruses and Biodefense
Shotgun Poster Session
Thursday, May 7, 2009
Oral Session 6: Mini-Symposium: Perspectives and Challenges in the Development of Topical Microbicides
Oral Session 7: Microbicides, Drug Design and Late Breaker Presentations
Abstracts
Complete Author Index
Invitation to the 23rd International Conference on Antiviral Research
Future International Conferences on Antiviral Research

Organization

International Society for Antiviral Research

and

Twenty-Second International Conference on Antiviral Research

Officers

President— Amy K. Patick, San Diego, California, USA

President-Elect—Joseph M. Colacino, South Plainfield, New Jersey, USA

Secretary—Susan Cox, Melbourne, Australia

Treasurer—Dale L. Barnard, Logan, Utah, USA

Past President—Christopher McGuigan, Cardiff, Wales, UK

ISAR Conference and Program Committees

Conference Chair: Chris McGuigan, Cardiff, Wales, UK

Program Chair: Robert W. Buckheit, Jr., Frederick, Maryland, USA

John A. Secrist III, Birmingham, Alabama, USA

Erik De Clercq, Leuven, Belgium

John C. Drach, Ann Arbor, Michigan, USA

José A. Esté, Barcelona, Spain

Charles E. McKenna, Los Angeles, California, USA

Chris Meier, Heidelberg, Germany

Amy K. Patick, San Diego California, USA

Leroy B. Townsend, Sedona, Arizona, USA

Donald Smee, Logan, Utah, USA

John Morrey, Logan, Utah, USA

Richard Pollard, Sacramento, California, USA

Mike Bray, Bethesda, Maryland USA

Richard Whitley, Birmingham, Alabama USA

Organizing Secretariats
Courtesy Associates	Chris McGuigan
2025 M Street, NW	Welsh School of Pharmacy
Suite 800	Cardiff University, Redwood Building
Washington, DC 20036	King Edward VII Avenue
USA	Cardiff, CF 10 3NB
	United Kingdom
Phone: +1 202 973 8690	Phone: +44 29 2087 4537
Fax: +1 202 331 0111	Fax: +44 29 2087 4537
E-mail: isar@courtesyassoc.com	E-mail: Mcguigan@cardiff.ac.uk

The International Society For Antiviral Research (ISAR)

The Society was organized in 1987 as a non-profit scientific organization for the purpose of advancing and disseminating knowledge in all areas of antiviral research. To achieve this objective, the Society organizes an annual meeting. The Society is now in its twenty-third year of existence, and has about 550 members representing 30 countries. For membership application forms or further information, please contact Dr. Susan Cox, Secretary, ISAR; Senior Vice President, Drug Development, Avexa Ltd., 576 Swan Street, Richmond, VIC 3121, Australia, telephone +61 3 9208 4066; fax +61 3 9208 4004; E-mail: scox@avexa.com.au. Membership application forms will also be available at the Conference Registration desk, or from our website www.isar-icar.com.

Contributors to the 22nd International Conference on Antiviral Research

Platinum

Gilead Sciences Inc., Foster City, CA, USA

Gold

Glaxo Smith Kline, Middlesex, United Kingdom

The International Partnership For Microbicides, Silver Spring, MD, USA

Silver

Boehringer Ingelheim (Canada) Ltd., Laval, Quebec, Canada

Genelabs Technologies, Inc., Redwood City, CA, USA

JCR Pharmaceuticals Co., Ltd. Ashiya, Japan

Pharmasset, Princeton, NJ, USA

Pfizer, New York, NY, USA

Romark, Tampa, FL, USA

Southern Research Institute, Birmingham, AL, USA

Tibotec, Mechelen, Belgium

Bronze

Abbott Laboratories, Abbott Park, IL, USA

Avexa Ltd., Richmond, Victoria, Australia

Biota Holdings, Melbourne, Victoria, Australia

Chimerix, Research Triangle Park, NC, USA

Elsevier, Amsterdam, The Netherlands

Idenix Pharmaceuticals, Cambridge, MA, USA

ImQuest BioSciences, Inc., Frederick, MD, USA

Microbiotix, Inc., Worcester, MA, USA

PTC Therapeutics Inc., South Plainfield, NJ, USA

Roche Palo Alto, Palo Alto, CA, USA

Toyama Chemical Co., Ltd., Tokyo, Japan

Vertex Pharmaceuticals, Inc., Cambridge, MA, USA

Additional Support Provided by:

Office of AIDS Research, National Institutes of Health, Bethesda, MD, USA

KEYNOTE ADDRESS

“Beautiful Biology But Bad Chemistry: Recognizing Chemistry Problems Earlier Rather Than Later”

Christopher Lipinski, Ph.D.

Sunday, May 3, 2009

5:00–6:00 p.m.

Mediterranean East

MINI-SYMPOSIA
“Development of Novel Therapies for HCV: Continuing the Fight”	“Clinical Update on Antiviral Drugs”
Monday, May 4, 2009	Tuesday, May 5, 2009
8:00–12:00 p.m.	1:00–4:00 p.m.
Mediterranean East	Mediterranean East

“Perspectives and Challenges in the Development Of Topical Microbicides”

Thursday, May 7, 2009

8:00–10:00 a.m.

Mediterranean East





SOCIAL EVENTS

Opening Reception

with light hors d’oeuvres

Sunday, May 3, 2009

6:00–8:00 p.m.

Grande Promenade

Conference Banquet

Wednesday, May 6, 2009

Reception

7:30 p.m.

Grande Promenade

Dinner and Program

8:00–10:00 p.m.

Grande Promenade

All Scientific and Social Events will be held in the Miami Beach Resort & Spa

Final Program

Twenty-Second International Conference on Antiviral Research

Sponsored by the

International Society for Antiviral Research

Miami Beach Resort & Spa

Miami Beach, Florida, USA

May 3–7, 2009

Sunday, May 3, 2009
Drug Discovery and Development 101
Chairs: Joe Colacino, Ph.D. and Amy Patick, Ph.D.
Mediterranean East
13:00–16:00
13:00	1.	Medicinal Chemistry and Lead Product Discovery
		Chris Lipinski, Ph.D.
		Melior Discovery, Waterford, CT, USA
14:00	2.	Product Development: Getting to the IND
		Shayne Gad, Ph.D.
		GAD Consulting Services, Cary, NC, USA
15:00	3.	ICAR Panelists: A Discussion of Development Successes and Failures: Karen Biron, Ph.D., Tomas Cihlar, Ph.D., Joe Colacino, Ph.D., Susan Cox, Ph.D., Phil Furman, Ph.D., Klaus Klumpp, Ph.D, Amy Patick, Ph.D., and Simon Tucker, Ph.D.
Opening Greetings
Mediterranean East
16:45–17:00
16.45	4.	Welcome to the 22nd ICAR
		Amy Patick, Ph.D.
		President, ISAR
16.50	5.	Welcome to Miami Beach
		Christopher McGuigan, Ph.D
		Chair, ICAR Conference Committee
16:55	6.	Introduction of the Keynote Speaker
		Joseph Colacino, Ph.D.
		President-Elect, ISAR
Keynote Address
Chairs: Joe Colacino, Ph.D
Mediterranean East
17:00–18:00
17:00	7.	Beautiful Biology But Bad Chemistry: Recognizing Chemistry Problems Earlier Rather Than Later
		Christopher Lipinski, Ph.D.
		Melior Discovery, Waterford CT, USA
Monday, May 4, 2009
Oral Session 1: Mini-Symposium: Development of Novel Therapies for Hepatitis C Virus (HCV): Continuing the Fight
Chairs: Phillip Furman, Ph.D. and Julian Symons, Ph.D.
Mediterranean East
08:00–12:00
08:00	8.	HCV and the Immune Response
		Stan Lemon, Ph.D.
		University of Texas Medical Branch, Galveston, TX, USA
08:30	9.	The Complexities of Hepatitis C Virus Entry
		Jane McKeating, Ph.D.
		University of Birmingham, United Kingdom
09:00	10.	Targeting Hepatitis C Virus NS2—An Unusual Protease with Multiple Functions
		Thomas Pietschmann, Ph.D.
		TWINCORE-Center for Experimental and Clinical Infection Research, Hannover, Germany
09:30		Break
10:00	11.	New Methods to Identify and Analyze HCV Helicase Inhibitors
		David Frick, Ph.D.
		New York Medical College, Valhalla, NY, USA
10:30	12.	New Targets Within Hepatitis C Virus NS4B
		Jeffrey Glenn, Ph.D.
		Stanford University School of Medicine, Stanford, CA, USA
11:00	13.	The Hepatitis C Virus NS5A: New Functions and New Mysteries
		Tim Tellinghuisen, Ph.D.
		The Scripps Research Institute, Jupiter, FL, USA
11:30		Panel Discussion
Elion Award Lecture
Mediterranean East
13:00	14.	Presentation of the Award
		Amy Patick, Ph.D.
		President, ISAR
13:10	15.	Award Lecture: Following Acyclovir—The Quest for a More Potent CMV Drug
		Karen Biron, Ph.D.
		Pathfinder Pharmaceuticals, Inc., Raleigh, NC, USA
Oral Session 2: Hepatitis Viruses
Chairs: Chris Roberts, Ph.D., and Klaus Klumpp, Ph.D.
Mediterranean East
13:45–16:00
13:45	16.	2′-Deoxy-Nucleoside Analogs can be Potent Dual Inhibitors of HCV and HIV Replication with Selectivity against Human Polymerases
		Klaus Klumpp1, Guoping Su1,2, Vincent Leveque1, Jerome Deval1, Gabrielle Heilek1, Sonal Rajyaguru1, Yu Li1, Julie Q. Hang1, Han Ma1, Nicole Inocencio1, Genadiy Kalayanov3, Anna Winqvist3, David B. Smith1, Nick Cammack1, Nils Gunnar Johansson3, Isabel Najera1
		1Roche, Palo Alto, CA, United States; 2Rigel, South San Francisco, CA; United States; 3Medivir, Huddinge, Sweden
14:00	17.	A Role for Nitazoxanide in Combination with STAT-C Agents for Inhibition of HCV Replication and the Potential for the Prevention of Viral Resistance
		Brent Korba1, Jeffery Glenn2, Menashe Elazar2, Jean-François Rossignol2,3
		1Georgetown University Medical Center, Washington, DC, United States; 2Stanford University School of Medicine, Stanford, CA, United States; 3The Romark Institute for Medical Research, Tampa, FL, United States
14:15	18.	Discovery and In Vitro Characterization of a Novel, Chain-terminating Tricyclic Nucleoside, Gl60630, With Potent Anti-HCV Activity
		Christopher Roberts, Jesse Keicher, Samantha Koo-McCoy, Derek Latour, Jeffrey Pouliot, Kevin Fung, John Zhang, Mohan Sivaraja, Mark Cunningham, Jill Bechtel, Lillian Lou, Natalia Dyatkina, Ting Wang, Wenbao Li, Amy K. Patick, Ronald Griffith
		Genelabs Technologies, Inc., Redwood City, CA, United States
14:30	19.	In Vitro Anti-Hepatitis C Virus (HCV) Activities and Resistance Profile of DEBIO 025—A Non-immunosuppressive Cyclophilin Binding Molecule
		Lotte Coelmont1, Philippe Gallay2, Michael Bobardt2, Suzanne Kaptein1, Jan Paeshuyse1, Inge Vliegen1, Grégoire Vuagniaux3, Johan Neyts1
		1Rega Institute, Leuven, Belgium; 2The Scripps Research Institute, La Jolla, CA, United States; 3Debiopharm, Lausanne, Switzerland
14:45	20.	DUY11—A Rigid Amphipathic Fusion Inhibitor, Inhibits HCV Infectivity By Modulating Membrane Curvature
		M St. Vincent1, A. Ustinov2, N. Barsby1, M. Joyce1, L. Tyrrell1, R. Epand3, R. Epand3, V. Korshun2, L. Schang1
		1Biochem and Med Micro & Immuno, University of Alberta, AB, Canada; 2Shemyakin-Ovchinnikov Institute, Russian Academy of Sciences, Russia; 3Biochem. & Biomed. Sci., McMaster University, ON, Canada
15:00	21.	Comparative Study of the Genetic Barrier and Pathways towards Resistance of Selective Inhibitors of HCV Replication
		Inge Vliegen, Leen Delang, Johan Neyts
		Rega Institute for Medical Research, KULeuven, Leuven, Belgium
15:15	22.	A Tetrazolo-pyrimidine Induces Intracellular Redistribution of Hepatitis B Surface Antigen, Resulting in Reduced Secretion
		Cally Goddard1, Haitao Guo2, Xiadong Xu1,3, Wenquan Yu1,3, Courtney Mills1, Timothy Block1,2, Andrea Cuconati1,3
		1Institute for Hepatitis and Virus Research, Doylestown, PA, United States; 2Drexel Institute for Biotechnology and Virology Research, Doylestown, PA, United States; 3Pharmabridge, Inc., Doylestown, PA, United States
15:30	23.	Inhibition of Hepatitis B Virus Replication by a Set of Small Interferon-stimulated Genes
		Haitao Guo1,2, Jessica Levy2, Dong Jiang1,2, Ju-Tao Guo1,2, Timothy Block1,2
		1Drexel Institute for Biotechnology and Virology Research, Drexel University College of Medicine, Doylestown, PA, United States; 2Institute for Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, PA, United States
15:45	24.	Administration of a HepDirectTM Prodrug of 2′-C-Methylcytidine to Hepatitis C Virus Infected Chimpanzees
		Steven Carroll1, Kenneth Koeplinger1, Marissa Vavrek1, Laurence Handt1, Malcolm MacCoss1, Scott Hecker2, David Olsen1
		1Merck Research Laboratories, West Point, PA, United States; 2Metabasis Therapeutics, San Diego, CA, United States
Poster Session 1: Retroviruses, Hepatitis Viruses, Respiratory Viruses, Emerging Viruses, and Antiviral Methods
Mediterranean West and Central
16:00–18:00
	25.	Antiviral Activity of Carbohydrate Binding Agents (CBAS) and the Role of DC-sign in Dengue Virus and HIV Infection
		Marijke Alen, Suzanne J.F. Kaptein, Tine De Burghgraeve, Johan Neyts, Jan Balzarini, Dominique Schols
		Rega Institute for Medical Research, Leuven, Belgium
	26.	Evaluation of the Anti-HIV Activity of Natalizumab—An Antibody against Integrin Alpha 4
		Ester Ballana1, Eduardo Pauls1, Gemma Moncunill1, Margarida Bofill1, Bonaventura Clotet1, Cristina Ramo-Tello2, José A. Esté1
		1Retrovirology Laboratory IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 2Neurology Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
	27.	Antiviral Activity of Unithiolum against the Human Immunodeficiency Virus and Herpes Simplex Virus
		Alla Fedchuk1, Victor Lozitsky2, Tatyana Gridina3, Svetlana Rybalko4, Dasha Fedorchenko5, Olga Maximenok6, Felix Ershov7, Olga Shcheglovitova8
		1Ukrainian Research Anti-Plague Institute, Odessa, Ukraine; 2Institute of Epidemiology and Infection Diseases, Kyiv, Ukraine; 3Research Institute of Epidemiology and Microbiology, Moscow, Russia
	28.	A Novel Small Molecule CCR5 Agonist, ESN-196, with Potent R5 HIV-1 Activity
		Thierry Ferain1, Dominique Schols2, Jérôme Bernard1, Graeme Fraser1
		1Euroscreen S.A., Gosselies, Belgium; 2Rega Institute for Medical Research, Leuven, Belgium
	29.	Human Immunodeficiency Virus Type 1 does not Escape from Novel Single-stranded Dnazyme Expression-mediated Inhibition
		Yuichiro Habu1,2, Ryuichi Sugiyama1, Hiroshi Takaku1
		1Chiba Institute of Technology, Narashino, Japan; 2Colorado State University, Fort Collins, CO, United States
	30.	In Silico Screening for Anti-HIV-1 Compounds Targeting to Human Cyclin T1
		Takayuki Hamasaki1,2, Masanori Baba1
		1Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, Japan; 2Japanese foundation for AIDS prevention, Tokyo, Japan
	31.	Predicted Models of Resistance and Hypersensitivity Conferred by Natural Polymorphisms of HIV-1 Integrase
		Raymond Hewer1, Telisha Traut1,2, Judy Coates1, Bradley Williams2
		1Mintek, Johannesburg, South Africa; 2University of Johannesburg, Johannesburg, South Africa
	32.	Synergistic Inhibition of Bovine Leukemia Virus Replication In Vitro by Ribavirin and Alpha-Interferon
		Jeffrey Isaacson1, Charles Wood2, Jay Reddy2
		1Nebraska Wesleyan University, Lincoln, NE, United States; 2Nebraska Center for Virology, University of Nebraska, Lincoln, NE, United States
	33.	Design of Artificial Polyepitope DNA Vaccine Constructs for Eliciting of HIV-specific CD8+ CTL Responses
		Svetlana Oreshkova, Sergey Bazhan, Pavel Belavin, Tatyana Ilyicheva, Sergey Seregin, Alexander Ilyichev, Larisa Karpenko
		State Research Center of Virology and Biotechnology Vector, Koltsovo, Novosibirsk region, Russia
	34.	Feglymycin—A Unique 13 Amino-acid Peptide, with a Novel Mechanism of Anti-HIV-1 Activity
		Dominique Schols1, Geoffrey Férir1, Bart Hoorelbeke1, Anne Hänchen2, Frank Dettner2, Roderich D. Süssmuth2
		1Rega Institute for Medical Research, Leuven, Belgium; 2Technische Universität Berlin, Berlin, Germany
	35.	Anti-HIV-1 Activity of A3g is Enhanced by Hsp70
		Ryuichi Sugiyama1, Yuichiro Habu2,3, Haruki Naganuma1, Hiroshi Koseki1, Ayako Furukawa4, Takashi Nagata4, Masato Katahira4, Hiroshi Takaku1,3
		1Department of Life and Environmental Science, Chiba Institute of Technology, Chiba, Japan; 2Department Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States; 3High Technology Research Center, Chiba Institute of Technology, Chiba, Japan; 4International Graduate School of Arts and Sciences, Yokohama City University, Kanagawa, Japan
	36.	Immediate and Persistent Anti-HIV-1 Activity of the Biguanide-based Compound NB325 Involves Specific Interactions with the Viral Co-Receptor CXCR4
		Nina Thakkar1, Vanessa Pirrone1, Shendra Passic1, Mohamed Labib2, Robert Rando2, Brian Wigdahl1, Fred Krebs1
		1Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States; 2Novaflux Biosciences, Inc., Princeton, NJ, United States
	37.	From β-Amino-γ-Sultone to New Bicyclic Pyridine and Pyrazine Heterocyclic Systems: Discovery of a Novel Class of HIV-1 Non-nucleoside Inhibitors
		Sonsoles Velazquez1, Sonia De Castro1, Jan Balzarini2, María-Jose Camarasa1
		1Instituto De Química Médica (C.S.I.C.), 28006 Madrid, Spain; 2Rega Institute For Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
	38.	A Small Llama Antibody Fragment Efficiently Inhibits the HIV Rev Multimerization In Vitro
		Thomas Vercruysse1, Els Pardon2, Jan Steyaert2, Dirk Daelemans1
		1Rega Institute For Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; 2Structural Biology Brussels, Vrije Universiteit Brussels, and Department of Molecular Interactions, VIB, B-1050 Brussels, Belgium
	39.	Study of the Retention of Metabolites of 4′-Ed4t—A Novel Anti-HIV-1 Thymidine Analog in Cells
		Xin Wang1, Hiromichi Tanaka2, Masanori Baba3, Yung-Chi Cheng1
		1Department of Pharmacology, Yale University School of Medicine, New Haven, CT, United States; 2School of Pharmaceutical Sciences, Showa University, Tokyo, Japan; 3Division of Antiviral Chemotherapy, Center For Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
	40.	A High-content Screening Approach to Identify Compounds that Interfere with the Formation of the Hepatitis C Virus Replication Complex
		J.M. Berke, D. Fenistein, F. Pauwels, O. Lenz, T.-I. Lin, E. Krausz, G. Fanning
		Tibotec BVBA, Generaal De Wittelaan L11B 3, 2800 Mechelen, Belgium
	41.	A Novel HCV Replication Mouse Model Using Human Hepatocellular Carcinoma Xenografts
		Carl Guévin, Alain Lamarre, Patrick Labonté
		INRS-Institut Armand-Frappier, Laval, QC, Canada
	42.	In Vitro Activity and In Vivo Pharmacokinetics of Highly Potent Phosphoramidate Nucleoside Analogue Inhibitors of Hepatitis C NS5B
		J. Hutchins1, S. Chanberlain1, C. Chang1, B. Ganguly1, E. Gorovits1, A. Hall1, G. Henson1, A. Kolykhalov1, Y. Liu1, J. Muhammad1, P. Perrone2, A. Gilles2, S. Holl2, K. Madela2, C. Mcguigan2, J. Patti1
		1Inhibitex, Alpharetta, GA, United States; 2Cardiff University, Cardiff, Wales
	43.	Hepatitis C Virus NS5A Protein In Vitro Modulates Template Selection by the RNA-dependent RNA Polymerase
		Olga Ivanova1, Vera Tunitskaya1, Alexander Ivanov1,2, Vladimir Mitkevich1,2, Vladimir Prassolov1, Alexander Makarov1, Marina Kukhanova1, Sergey Kochetkov1
		1Engelhardt Institute of Molecular Biology, Moscow, Russia; 2University of Oslo, Center For Medical Studies In Russia, Moscow, Russia
	44.	Comparison of Various Combination Therapies for the Treatment of Yellow Fever Virus
		Justin Julander1, Don Smee1, John Morrey1, Yousuke Furuta2
		1Institute For Antiviral Research, Logan, UT, United States; 2Toyama Chemical Co., Ltd., Tokyo, Japan
	45.	A New Series of Tricyclic Nucleosides as Potent Inhibitors of Hepatitis C Virus RNA Replication: Design, Synthesis and Structure–Activity Relationships
		Jesse Keicher, Natalia Dyatkina, Xiaoling Zheng, Vivek Rajwanshi, Marija Prhavc, Samantha Koo-Mccoy, Kevin Fung, Derek Latour, Mohan Sivaraja, Uli Schmitz, Christopher Roberts, Ronald Griffith
		Genelabs Technologies, Redwood City, CA, United States
	46.	Phosphoramidate Protides Greatly Enhance the Anti-HCV Activity of 2′-Methylguanosine
		Karolina Madela1, Plinio Perrone1, Arnaud Gilles1, Johan Neyts2, Chris Mcguigan1
		1Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; 2Rega Institute For Medical Research, Leuven, Belgium
	47.	Use of the Bellocell System to Determine the Optimal Dose of Ribavirin to Inhibit the Expression of an HCV Replicon in 2209-23 Cells
		James Mcsharry, Diane Singer, Robert Kulawy, Ashley Brown, George Drusano
		Ordway Research Institute, Albany, NY, United States
	48.	Silibinin (Legalon-Sil) Inhibits HCV Replication In Vitro
		Isabel Najera1, Vincent Leveque1, Matt Mccown1, Julie Q. Hang1, Han Ma1, Sonal Rajyaguru1, Amy Fung1, Yanli Yang1, Yang Liu1, Simran Kular1, Nick Cammack1, Peter Ferenci2, Klaus Klumpp1
		1Roche, Palo Alto, CA, United States; 2Medical University of Vienna, Vienna, Austria
	49.	Therapeutic Efficacy of the Amphipathic DNA Polymer REP 9AC in the Treatment of Duck Hepatitis B Virus Infection In Vivo
		Faseeha Nordeen1, Arend Grosse1,2, Jean-Marc Juteau3, Andrew Vaillant3, Allison Jilbert1,2
		1School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, Australia; 2Infectious Diseases Laboratories, SA Pathology, Adelaide, Australia; 3Replicor Inc., Laval, QC, Canada
	50.	Characterization of the Mechanism of Action of PG-301029: A Novel Late Stage Inhibitor of HCV Replicon Replication
		Todd Parsley, Lu Yang, Robert W. Buckheit, Jr.
		Imquest Biosciences, Inc., Frederick, MD, United States
	51.	Predictive Factors to Response to Interferon Therapies for Treatment-naive Patients Infected with Hepatitis C Virus in Islamabad and Vicinity Areas: A Study From Pakistan
		Abida Raza, Hafsa Aziz, Javed Irfan
		Nuclear Medicine Oncology and Radiotherapy Institute, Islamabad, Pakistan
	52.	Design, Molecular Modelling Studies of Specific Targeted Candidate Inhibitors of HCV NS5B RNA Polymerase
		P. Selvam1, M. Chandramohan2, J. Pranitha3, N. Saravanan Prabhu3, Muthuvels Suresh Kumar 3
		1Amrita School of Pharmacy, AIMS Campus, Kochi-26, India; 2Bharat Ratna Kamarajar Jaundice, Liver Hospital and Research Centre, Madurai 01, India; 3Centre For Bioinformatics, Pondicherry University, Puducherry-14, India
	53.	Identification and Characterization of Pyrimidinediones as Potent Non-nucleoside Reverse Transcriptase Inhibitors of Hepatitis B Virus
		Lu Yang, Todd Parsley, Robert W. Buckheit, Jr.
		ImQuest BioSciences, Inc., Frederick, MD, United States
	54.	Prophylactic Efficacy of Intranasally Administered HSP Nanoparticles for Treating a Lethal SARS-CoV Infection in Balb/C Mice
		Dale Barnard1, James Wiley2, Miles Wandersee1, Yohichi Kumaki1, Mark Young2, Trevor Douglas2, Allan Harmsen2
		1Utah State University, Logan, UT, United States; 2Montana State University, Bozeman, MT, United States; 3 United States; 4 United States
	55.	The Activity of New Cage Compounds Against Avian Influenza Virus (H5N1)
		Evgeny Belanov1, Marina Leonova2, Vladimir Osyanin2, Pavel Krasnikov2, Sergey Kuznetsov2, Andrey Shiraev2, Evgeny Golovin2, Olga Serova1, Nikolay Bormotov1, Sergei Balakhnin1, Yurii Klimochkin2
		1FSRI SRC VB “Vector” Rospotrebnadzor, Novosibirsk, Russia; 2Samara State Technical University, Samara, Russia
	56.	Oseltamivir-resistant Subpopulations of H5N1 Influenza Variants are Genetically Stable and Virulent in Ferrets
		Elena A. Govorkova, Natalia A. Ilyushina, Jennifer L. Mcclaren, Robert G. Webster
		St. Jude Children's Research Hospital, Memphis, TN, United States
	57.	Inhibition of Influenza Virus Replication: Discovery and Development of Therapeutic Compounds which Suppress Viral RNA Synthesis
		Tracy Hartman, Robert W. Buckheit, Jr.
		ImQuest BioSciences, Inc., Frederick, MD, United States
	58.	Combinations of 5-Iodo-4′-Thio-2′-Deoxyuridine and ST-246 or CMX001 Synergistically Inhibit Orthopoxvirus Replication In Vitro
		Kathy Keith1, Shalisa Sanders1, Kamal Tiwari2, Joseph Maddry2, John Secrist2, Robert Jordan3, Dennis Hruby3, Randall Lanier4, George Painter4, Earl Kern1, Mark Prichard1
		1University of Alabama School of Medicine, Birmingham, AL, United States; 2Southern Research Institute, Birmingham, AL, United States; 3SIGA Technologies Inc., Corvallis, OR, United States; 4Chimerix Inc., Research Triangle Park, NC, United States
	59.	Induction of Interferon Gamma Inducible Protein 10 By SARS-CoV Infection, Interferon Alfacon 1 and Interferon Inducer in Human Bronchial Epithelial Calu-3 Cells and Balb/C Mice
		Yohichi Kumaki, Craig W. Day, Miles K. Wandersee, Jason R. Madsen, John D. Woolcott, Justin D. Hoopes, Kevin W. Bailey, Min-Hui Wong, Donald F. Smee, John D. Morrey, Dale L. Barnard
		Institute For Antiviral Research, Logan, UT, United States
	60.	Anti-Influenza Efficacy of Combination Apply of Proteolytic Inhibitor E-Aminocaproic Acid with Neuraminidase Inhibitor Tamiflu
		V. Lozitsky1, A. Frolov2, A. Fedchuk1, T. Grydina1, L. Mudrik1, L. Shitikova1, L. Socheslo1, V. Zadorozhnaya2
		1RAPI, Odesa, Ukraine; 2NCI&ARI, Kiev, Ukraine
	61.	Structure–Activity Relationship of a Novel Class of Aglycoristocetin Derivatives with Potent and Broad Activity Against Influenza Viruses
		Lieve Naesens1, Evelien Vanderlinden1, Erzsébet Rőth2, József Jekő2, Graciela Andrei1, Robert Snoeck1, Christophe Pannecouque1, Eszter Illyés3, Gyula Batta2, Pál Herczegh2, Ferenc Sztaricskai2
		1Rega Institute For Medical Research, Leuven, Belgium; 2Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary; 3Department of Chemistry, Eötvös Loránd University, Budapest, Hungary
	62.	Cinnamon Fraction Neutralizes Avian Influenza H5N1 both In Vitro and In Vivo
		Michael Ovadia, Immanuel Kalily, Emily Bernstein
		Tel-Aviv University, Ramat-Aviv, Israel
	63.	Comparative Study of the Efficacy of Low- and High-molecular Inhibitors of Influenza Virus Hemagglutinin
		S. Rak1, E. Goncharova1, I. Vinogradov1, E. Ryabchikova1, A. Chinarev2, A. Tuzikov2, N. Bovin2, A. Ryzhikov1
		1FSRI SRC VB Vector, Koltsovo, Russia; 2Shemyakin Institute of Bioorganic Chemistry, Moscow, Russia
	64.	The Antiviral Effect of a Novel Inhibitor of Influenza Virus Hemagglutinin on Influenza A (H5N1) Virus
		Svetlana Rak1, Elena Goncharova1, Alexander Chinarev2, Alexander Tuzikov2, Nicolai Bovin2, Alexander Ryzhikov1
		1FSRI SRC of Virology and Biotechnology Vector, Koltsovo, Russia; 2Shemyakin Institute of Bioorganic Chemistry, Moscow, Russia
	65.	In Vitro Anti-Influenza Virus Effect of a Protease Inhibitor from a Streptomyces Strain
		Julia Serkedjieva1, Lidia Angelova-Duleva1,2, Iskra Ivanova2
		1Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria; 2Department of Microbiology, Sofia University, Sofia, Bulgaria
	66.	Protective Effect of a Fungal Superoxide Dismutase Combined with a Plant Polyphenol Extract and Rimantadine Hydrochloride in the Murine Experimental Influenza Virus Infection
		Julia Serkedjieva, Maria Angelova
		Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria
	67.	Discovery of New Inhibitors of the Influenza H5N1 Virus
		William Severson1, Xi Chen1, Joseph Maddry1, Yong-Kyu Chu1, Colleen Jonsson1, Alexis Mcbrayer1, Ronald Tapp1, Donald Smee2, Clinton Maddox1, Subramaniam Ananthan1, James Noah1, Leland Black1, Blake Moore1, Melinda Sosa1, Lucile White1, Lynn Rasmussen1
		1Southern Research Institute, Drug Discovery Division, Birmingham, AL, United States; 2Institute For Antiviral Research, Logan, UT, United States
	68.	Rimantadine and Oseltamivir Combination Effects in a Therapeutic Course of Application Against Influenza A (H3N2) in Mice
		Lora Simeonova, Galina Gegova, Angel S. Galabov
		Institute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria
	69.	Combination of Neuraminidase Inhibitors with T-705 for Treating Influenza Virus Infections in Cell Culture and in Mice
		Donald Smee1, Min-Hui Wong1, Kevin Bailey1, John Morrey1, Masako Maekawa2, Kazumi Takahashi2, Yousuke Furuta2
		1Utah State University, Logan, UT, United States; 2Toyama Chemical Co., Ltd., Toyama, Japan
	70.	High-Throughput Screening of Protease Inhibitor Libraries Using a Novel Dual Pseudotype-based Assay for SARS-CoV Entry
		Yanchen Zhou, Kai Lu, Juliet Agudelo, Graham Simmons
		Blood Systems Research Institute, and University of California, San Francisco, San Francisco, CA, United States
	71.	Pichinde Virus Induces Endothelial Cell Monolayer Permeability Through the Production of Nitric Oxide
		Rebecca Brocato, Thomas Voss
		Tulane School of Medicine, Department of Microbiology and Immunology, New Orleans, LA, United States
	72.	Novel Small Molecule Inhibitors of Dengue Virus Replication
		Chelsea Byrd, Jessica Page, Chris Harver, Doug Grosenbach, Aklile Berhanu, Dennis Hruby, Robert Jordan
		SIGA Technologies, Corvallis, OR, United States
	73.	Escaping Development of Drug-Resistant Mutants: Basis for Effective Chemotherapy of Enterovirus Infections
		Angel S. Galabov1, Ralitsa Vassileva-Pencheva1, Ivanka Nikolova1, Boris Atanassov2
		1Institute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria; 2Institute of Organic Chemistry, Bulg. Acad. Sci., Sofia, Bulgaria
	74.	Escaping Development of Drug-Resistant Mutants: Basis for Effective Chemotherapy of Enterovirus Infections
		Angel S. Galabov1, Ralitsa Vassileva-Pencheva1, Ivanka Nikolova1, Boris Atanasov2
		1The Stephan Angeloff Institute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria; 2Institute of Organic Chemistry, Bulg. Acad. Sci., Sofia, Bulgaria
	75.	Arenaviral Inhibitory Activity of MY-24—A Novel Aristeromycin Derivative
		Brain Gowen1, Kie-Hoon Jung1, Wei Ye2, Min-Hui Wang1, Deanna Larson1, Donald Smee1, John Morrey1, Stewart Schneller2
		1Institute For Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, UT, United States; 2Chemistry & Biochemistry Department, Auburn University, Auburn, AL, United States
	76.	Pyrazine Derivative Treatment of Phleboviral Infection in Cell Culture and Rodent Model Systems
		Brian Gowen1, Min-Hui Wong1, Kie-Hoon Jung1, Donald Smee1, John Morrey1, Yousuke Furuta2
		1Utah State University, Logan, UT, United States; 2Research Laboratories, Toyama Chemical Company, Ltd., Toyama, Japan
	77.	FGI-104: A Broad-Spectrum Small Molecule Inhibitor of Viral Infection
		Michael Kinch1, Abdul Yunus1, Hanwen Mao1, Calli Lear2, Guangxiang Luo3, Michael Murray4, Zhuhui Huang4, Zena Fesseha1, Hanson Chen1, Gene Olinger2, Michael Goldblatt1
		1Functional Genetics, Inc., Gaithersburg, MD, United States; 2United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, United States; 3Department of Microbiology Immunology and Molecular Genetics, Lexington, KY, United States; 4Hepatitis Research Program, Frederick, MD, United States
	78.	Derivatives of Tunicamycin as Effective Inhibitors of Classical Swine Fever Virus
		Ewelina Krol1, Ilona Wandzik3, Boguslaw Szewczyk1, Grzegorz Grynkiewicz2, Wieslaw Szeja3
		1Department of Molecular Virology, University of Gdansk, Gdansk, Poland; 2Pharmaceutical Institute, Warsaw, Poland; 3Silesian Technical University, Gliwice, Poland
	79.	Anti-Picornavirus Activity and other Antiviral Activity of Sulfated Exopolysaccharide from the Marine Microalga Gyrodinium impudicum Strain KG03
		Chong-Kyo Lee1, Hae Soo Kim1, Ju Ryung Nam1, Myung-Jin Lee1, Joung-Han Yim2, Hong Kum Lee2, Erik De Clercq3
		1Pharmacology Research Center, Korea Research Institute of Chemical Technology (KRICT), 305-600 Daejeon, Korea; 2Polar Biocenter, Korea Polar Research Institute (KOPRI), 406-840 Incheon, Korea; 3Rega Institute For Medical Research, K.U.Leuven, 3000 Leuven, Belgium
	80.	Assay Development for Antiviral Drug Efficacy Evaluation against Dengue Virus
		Qianjun Li
		University of Alabama At Birmingham, Birmingham, AL, United States
	81.	Structural Basis of the Disoxaril Resistance and Dependence of Coxsackievirus B1
		Ivanka Nikolova1, Angel S. Galabov1, Rumena Petkova2, Stoyan Chakarov3, Boris Atanasov4
		1Institute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria; 22Scientific Technological Service, Ltd., Sofia, Bulgaria; 33Department of Biochemistry, Sofia University, Sofia, Bulgaria; 4Institute of Organic Chemistry, Bulg. Acad. Sci., Sofia, Bulgaria
	82.	Anti-Adenoviral Activity of 6-Azanucleoside Analogues
		Lidiya Nosach1, Olga Povnitsa1, Inna Alexeeva2, Larisa Palchikovska2, Nadezhda Nesterova1
		1Institute of Microbiol. & Virol., NAS of Ukraine, Kiev, Ukraine; 2Institute of Mol. Biol. & Genetic NAS of Ukraine, Kiev, Ukraine
	83.	Antiviral Activity of Octadecyloxypropyl Esters of 3-Hydroxy-2-(Phosphonomethoxy)Propyl Nucleosides against Adenovirus In Vitro
		J.P. Roth1, T.Z. Mclean1, N. Valiaeva2, J.R. Beadle2, K.Y. Hostetler2, D.L. Barnard1
		1Institute For Antiviral Research, Utah State University, Logan, UT, United States; 2Division of Infectious Disease, University of California, San Diego, La Jolla, CA, United States
	84.	Indole Derivatives are Potent Inhibitors of HIV Integrase
		Periyasamy Selvam1, Kasthuraiah Maddali2, Yves Pommier2
		1Dept. of Medicinal Chemistry, Amrita School of Pharmacy, Kochi 26, India; 2Laboratory of Molecular Pharmacology, Centre For Cancer Research, NCI, NIH, Bethesda, WA, United States
	85.	The Antiproliferative Effects of Octadecyloxyethyl-phosphonomethoxyethylguanine (Ode-Pmeg) on the Growth of Human Papilloma Virus Positive Cervical Carcinoma (ME-180) Cells In Vitro and Solid Tumors in Athymic Nude Mice
		Julissa Trahan, Kathy Aldern, Karl Hostetler
		University of California San Diego and The Veterans Medical Research Foundation, San Diego, CA, United States
	86.	Antiviral Activity of Geneticin Against Dengue Virus
		Xianchao Zhang1, Peter Mason2, Edward Dubovi3, Alex Birk1
		1Institute For Hepatitis and Virus Research, Doylestown, PA, United States; 2University of Texas Medical Branch, Galveston, TX, United States; 3Cornell University, Ithaca, NY, United States
Tuesday, May 5, 2009
Oral Session 3: Retroviruses
Chairs: Jan Balzarini, Ph.D. and Ronald Swanstrom, Ph.D
Mediterranean East
08:00–11:30
08:00	87.	Plenary: A Strong Dominant Negative Mutation in the HIV-1 Gag Protein Defines a New Drug Target
		Ronald Swanstrom, Ph.D.
		The University of North Carolina, Chapel Hill, NC, USA
08:30	88.	Small-molecule CCR5 Ligands that may Spare the CCR5 Function: Opportunity for New Antiviral Discovery?
		Wieslaw Kazmierski, Vanessa Muniz-Medina, Susan Danehower, Stacey Jones, Terry Kenakin
		Glaxosmithkline, Research Triangle Park, NC, United States
08:45	89.	Development of Hexadecyloxypropyl Tenofovir (CMX157) for HIV: Potential for use as a Microbicide and Therapeutic
		Randall Lanier, Bernhard Lampert, Lawrence Trost, Merrick Almond, George Painter
		Chimerix Inc, Durham, NC, United States
09:00	90.	Toward Unsymmetrical CADA Analogs as Novel Down-modulators of the CD4 Receptor
		Violeta Demillo1, Sreenivasa Anugu1, Kurt Vermeire2, Dominique Schols2, Thomas Bell1
		1Department of Chemistry, University of Nevada, Reno, NV, United States; 2Rega Institute For Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
09:15		Break
09:45	91.	Pradimicin-S is a Highly Soluble Non-peptidic Small-size Carbohydrate-binding Antibiotic that may Qualify as a Potential Drug Lead for HIV Treatment
		J. Balzarini1, K. François1, K. Van Laethem1, B. Hoorelbeke1, J. Auwerx1, S. Liekens1, Y. Igarashi2, T. Oki3, D. Schols1
		1Rega Institute For Medical Research, K.U. Leuven, B-3000 Leuven, Belgium; 2Biotechnology Research Center, Toyama Prefectural University, Toyama 939-0398, Japan; 3Shoda, Sakae, Yokohama 247-0022, Japan
10:00	92.	Highly Potent and Dual Acting Pyrimidinedione Inhibitors of HIV-1 Possess a High Genetic Barrier to Resistance
		Robert W. Buckheit, Jr., Karen Watson, Tracy Hartman, Lu Yang
		ImQuest BioSciences, Inc., Frederick, MD, United States
10:15	93.	Design, Synthesis and Anti-HIV-1 Evaluation of Novel Arylazolylthioacetanilides as Potent NNRTIs
		Xinyong Liu1, Peng Zhan1, Christophe Pannecouque2, Erik De Clercq2
		1Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, China; 2Rega Institute For Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, Leuven, Belgium
10:30	94.	ZNRD1 as a Host Cellular Factor Influencing HIV-1 Replication
		Ester Ballana, Jordi Senserrich, Eduardo Pauls, Josep Maria Mercader, Bonaventura Clotet, Lidia Ruiz, Jorge Gallego, Frédéric Uyttebroeck, Amalio Telenti, Angela Cuiffi, José A. Esté
		Retrovirology Laboratory Irsicaixa, Hospital Universitari Germans Trias I Pujol, Universitat Autònoma De Barcelona, Badalona, Spain
10:45	95.	CXCR4 Chemokine Receptor Antagonists from Ultra Rigid Metal Complexes Profoundly Inhibit HIV-1 Replication and also AMD3100-resistant Strains
		Stephen J. Archibald1, Dirk Daelemans2, Timothy J. Hubin3, Dana Huskens2, Dominique Schols2, Kristel Van Laethem2, Erik De Clercq2, Christophe Pannecouque2
		1Department of Chemistry and Clinical Biosciences Institute, University of Hull, Hull, HU6 7RX, United Kingdom; 2Rega Institute For Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; 3Department of Chemistry and Physics, Southwestern Oklahoma State University, OK 73096, United States
11:00	96.	High-throughput In Vitro HIV Rev-multimerization Assay
		Thomas Vercruysse1, George Pavlakis2, Dirk Daelemans1
		1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven 3000, Belgium; 2Human Retrovirus Pathogenesis Section, National Cancer Institute, Frederick 21702-1201, MD, United States
11:15	97.	Pre-clinical Development of IQP-0410—A Highly Potent Dual-acting Agent for the Therapy of HIV-1 Infection
		Nick Kaludov, Karen Watson, Robert Buckheit, Jr.
		ImQuest BioSciences Inc., Frederick, MD, United States
Clinical Symposium
Chairs: Richard Pollard, M.D. and Richard Whitley, M.D.
Mediterranean East
13:00–16:00
Poster Session 2: Herpesviruses, Poxviruses, Other Antiviral Agents, Medicinal Chemistry And Topical Microbicides
Mediterranean West and Central
16:00–18:00 p.m.
	98.	Antiviral Activity of Monoterpene Components of Essential Oils Against Herpes Simplex Virus
		Akram Astani1, Jürgen Reichling2, Paul Schnitzler1
		1 Department of Virology, Hygiene Institute, University of Heidelberg, Heidelberg, Germany; 2 Department of Biology, Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany
	99.	Preclinical Pharmacokinetic, Toxicokinetic and Toxicology Results for Cyclopropavir—A Promising New Agent for the Treatment of Beta- and Gamma-Herpesviruses
		Terry Bowlin1, Jennifer Brooks1, Jiri Zemlicka2
		1Microbiotix, Inc., Worcester, MA, United States; 2Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States
	100.	Phenotyping Human Cytomegalovirus Drug Resistance Mutations Using a Recombinant Virus Incorporating EGFP
		Meike Chevillotte1, Hans A. Kestler2, Thomas Mertens1, Jens Von Einem1
		1Institute of Virology, University Hospital, Ulm, Germany; 2Internal Medicine I, University Hospital, Ulm, Germany
	101.	The Effect of Human Cytomegalovirus Proteins Pul97 and Pul27 on Host Interferon Responses
		Rachel Gill, Etty Benveniste, Mark Prichard
		University of Alabama School of Medicine, Birmingham, AL, United States
	102.	Mutation of the Thymidine Kinases Encoded by Herpes Simplex Virus or Vaccinia Virus can confer Resistance to 5-Iodo-4′-Thio-2′-Deoxyuridine
		Emma Harden1, Kathy Keith1, Shannon Daily1, Kamal Tiwari2, Joseph Maddry2, John Secrist2, Earl Kern1, Mark Prichard1
		1University of Alabama School of Medicine, Birmingham, AL, United States; 2Southern Research Institute, Birmingham, AL, United States
	103.	Conserved Retinoblastoma Protein-binding Motifs in Human Cytomegalovirus UL97 Minimally Impact Viral Replication But Can Affect Susceptibility to Maribavir
		Caroll Hartline1, Rachel Gill1, Samuel Frederick1, Sunwen Chou2, Mark Prichard1
		1University of Alabama School of Medicine, Birmingham, AL, United States; 2Oregon Health and Science University, Portland, OR, United States
	104.	Antiviral Activities of Nucleoside Analogs Against HSV-1 Replication in 143B Cells Expressing the Viral Tk Genes with Different Initiation Codon Sites
		Chong-Kyo Lee, Ju Ryung Nam, Myung-Jin Lee, Hae Soo Kim
		Korea Research Institute of Chemical Technology, Daejeon, Korea, Korea
	105.	A Study of the Safety and Pharmacokinetics of Multiple Ascending Doses of FV-100 in Healthy Subjects
		Mark Matson1, Helen Pentikis2, Brian Boehlecke3, Eric Wenzel4, Geoff Henson4, Amy Morris4
		1Prism Research Inc., St. Paul, MN, United States; 2SAJE Consulting LLC, Baltimore, MD, United States; 3Rho Inc., Chapel Hill, NC, United States; 4Inhibitex, Inc., Alpharetta, GA, United States
	106.	A Study of the Safety and Pharmacokinetics of Single and Multiple Doses of FV-100 in Subjects 65 years and Over.
		Mark Matson1, George Atiee2, Helen Pentikis3, Brian Boehlecke4, Eric Wenzel5, Amy Morris5
		1Prism Research Inc., St. Paul, MN, United States; 2ICON Plc., San Antonio, TX, United States; 3SAJE Consulting LLC, Baltimore, MD, United States; 4Rho Inc., Chapel Hill, NC, United States; 5Inhibitex Inc., Alpharetta, GA, United States
	107.	Study of Anti Epstein-Barr Virus Activity of Novel Fluorinated Heterocyclic Nucleoside Analogues
		N. Nesterova1, Yu. Shermolovich2, S. Zagorodnya1, A. Golovan1, O. Kanishchev2, G. Baranova1
		1Zabolotny Institute of Microbiology and Virology, NAS of Ukraine, Kyiv, Ukraine; 2Institute of Organic Chemistry, NAS of Ukraine, Kyiv, Ukraine
	108.	Study of Anti Epstein-Barr Virus Activity of Novel Fluorinated Heterocyclic Nucleoside Analogues
		N. Nesterova1, Yu. Shermolovich2, S. Zagorodnya1, A. Golovan1, O. Kanishchev2, G. Baranova1
		1Zabolotny Institute of Microbiology and Virology, NAS of Ukraine, Kyiv, Ukraine; 2Institute of Organic Chemistry, NAS of Ukraine, Kyiv, Ukraine
	109.	Induction of Lytic Cytotoxicity by NF-KB Inhibitors in Epstein-Barr Virus-associated Gastric Carcinoma Cells
		Paula Ordonez Suarez1, Chihaya Koriyama1, Yoshito Eizuru2, Suminori Akiba1
		1Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; 2Division of Oncogenic and Persistent Viruses, Center For Chronic Viral Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
	110.	Anti-Cytomegalovirus Activity of Membranotropic Polyacidic Agents Effects In Vitro
		M. Pavlova1, A. Serbin2, N. Fedorova1, E. Karaseva2, E. Klimova1, A. Kushch1
		1Ivanovski Virology Inst., Moscow, Russia; 2Health RDF, Moscow, Peru
	111.	A Mass Spectrometry-based Method to Detect Antiviral Drug Resistance in Human Cytomegalovirus
		Clara Posthuma, Martha Van Der Beek, Caroline Van Der Blij, Willy Spaan, Louis Kroes, Eric Snijder
		Leiden University Medical Center, Leiden, Netherlands
	112.	l-Analogs of 1-Beta-d-Ribofuranosyl-2-Bromo-5,6-Dichlorobenzimidazole (BDCRB) inhibit Human Herpesvirus-6 Replication
		Mark Prichard1, Samuel Frederick1, Shannon Daily1, Kathy Borysko2, Julie Breitenbach2, Leroy Townsend2, John Drach2
		1The University of Alabama School of Medicine, Birmingham, AL, United States; 2School of Dentistry and College of Pharmacy, University of Michigan, Ann Arbor, MI, United States
	113.	Comparative Efficacy of Treatment with CMX001 Versus Acyclovir in Balb/C Mice Infected with Herpes Simplex Virus
		Debra Quenelle1, Mark Prichard1, Emma Harden1, Deborah Collins1, Terri Rice1, George Painter2, Alice Robertson2, Earl Kern1
		1University of Alabama School of Medicine, Birmingham, AL, United States; 2Chimerix, Inc., Durham, NC, United States
	114.	Compounds that Target Host Cell Enzymes Prevent Varicella-Zoster Virus Replication In Vitro, Ex Vivo, and In SCID-HU Mice
		J. Rowe, R. Greenblatt, D. Liu, J. Moffat
		SUNY Upstate Medical University, Syracuse, NY, United States
	115.	Evaluation of Octadecyloxyethyl Esters of 3-Hydroxy-2-(Phosphonomethoxy)Propyl Nucleosides against HCMV, HSV and Poxviruses
		Nadejda Valiaeva1, Julissa Trahan1, Kathy A. Keith2, Caroll Hartline2, Mark Prichard2, James R. Beadle1, Karl Y. Hostetler1
		1University of California, San Diego, and The Veterans Medical Research Foundation, La Jolla, CA, United States; 2University of Alabama, Birmingham, AL, United States
	116.	Effects of Antivirals via Intratympanic Delivery in GPCMV Related Hearing Loss
		Jonette Ward1, Daniel Choo1,2
		1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; 2University of Cincinnati, Cincinnati, OH, United States
	117.	Inhibition of Herpes Simplex Virus by Polyamines
		Ira Yudovin-Farber1, Irina Gurt2, Ronen Hope2, Abraham J. Domb1, Ehud Katz2
		1Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Faculty of Medicine, Hebrew University, Jerusalem, Israel; 2Department of Virology, Hadassah Medical School, Hebrew University, Jerusalem, Israel
	118.	Characterization of Cowpox Virus (CPV) Mutants Arising under Pressure with Different Acyclic Nucleoside Phosphonates
		Graciela Andrei, Pierre Fiten, Erik De Clercq, Ghislain Opdenakker, Robert Snoeck
		Rega Institute, Leuven, Belgium
	119.	Interactions between the Human Oligopeptide Transporter, HPEPT1 and Serine Side Chain-linked Cidofovir Prodrugs
		Monica Sala-Rabanal1, Larryn W. Peterson2, Michaela Serpi2, Ivan S. Krylov2, Boris A. Kashemirov2, Jae Seung Kim3, Stefanie Mitchell3, John M. Hilfinger3, Charles E. Mckenna2
		1Department of Physiology, David Geffen School of Medicine, UCLA, Los Angeles, CA, United States; 2Department of Chemistry, University of Southern California, Los Angeles, CA, United States; 3TSRL, Inc., Ann Arbor, MI, United States
	120.	Compounds Designed to Bind Conserved Regions of Human Papillomavirus (HPV) DNA Show Broad-spectrum Activity Against High-risk Genotypes
		James Bashkin1,2, Terri Edwards2, Kevin Koeller1, Terri Edwards2, Urszula Slomczynska1, Chris Fisher2
		1University of Missouri-St. Louis, St. Louis, MO, United States; 2Nanovir, Kalamazoo, MI, United States
	121.	Synthesis and Biological Studies of Mutagenic Ribonucleoside Analogues as Potential Inducers of Error Catastrophe of Riboviruses
		María-José Camarasa1, Ana San-Félix1, M. Teresa Peromingo1, Mercedes Dávila2, Ana I. De Avila2, Rubén Agudo2, Esteban Domingo2
		1Instituto De Química Médica (CSIC), Madrid, Spain; 2Centro De Biología Molecular “Severo Ochoa” (CSIC), Madrid, Spain
	122.	Antiflogistics as Viral Inhibitors
		Georgy Danilenko1, Svitlana Rybalko2, Tatiana Bukhtiarova3, Valentina Danilenko3, Svitlana Guzhova1, Victor Lozitsky4
		1institute Organic Chemistry, Kyiv, Ukraine; 2Institute Epidemiology, Kyiv, Ukraine; 3Institute Pharmacology, Kyiv, Ukraine; 4Institute Pharmacology, Kyiv, Ukraine; 5Institute Organic Chemistry, Kyiv, Ukraine; 6Anti-Plague Institute, Odessa, Ukraine
	123.	Synthesis, Antiviral Activity, and Cytotoxicity of Some Novel 2-Phenyl-3-Disubstituted Quinazolin-4(3H)-ones
		Periyasamy Selvam1, Julie M. Breitenbach2, Katherine Z. Borysko2, John C. Drach2
		1Amrita School of Pharmacy, AIMS Campus, Elamakkara, Kochi-682026, India, Kochi, India; 2School of Dentistry and College of Pharmacy, University of Michigan, Ann Arbor, MI, United States
	124.	Expression of Infectious Bursal Disease Virus (IBDV) Polyprotein and VP4 Protease
		Phillia Vukea, Alain Boulange, Theresa Coetzer
		University of Kwa-Zulu-Natal, Pietermaritzburg, South Africa
	125.	Synthesis and SAR of 9-Arylpurines As Novel Inhibitors of Enterovirus Replication
		Leire Aguado1, Hendrik Jan Thibaut2, María-José Camarasa1, Johan Neyts2, María-Jesús Pérez-Pérez1
		1Instituto De Química Médica (CSIC), 28006 Madrid, Spain; 2Rega Institute For Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
	126.	HIT QSAR Study of Antivirals’ Bioavailability
		Anatoly Artemenko1, Eugene Muratov1,2, Victor Kuz’min1, Maxim Kulinskij1, Irina Borisuk1, Nikolay Golovenko1, Alexander Tropsha2
		1A.V. Bogatsky Physical-Chemical Institut, Odessa, Ukraine; 2University of Nort Carolina, Chapel Hill, NC, United States
	127.	Synthesis and Evaluation of Novel Acyclovir Phosphoramidates as Anti-HIV Agents
		Davide Carta1, Christopher Mcguigan1, Leonid Margolis2, Jan Balzarini3
		1Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; 2Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States; 3Rega Institute For Medical Research, Leuven, Belgium
	128.	Design, Synthesis and SAR of New Potent HIV-1 RT Inhibitors
		Alba Chimirri1, Erik De Clercq2, Giovanni Maga3, Patrizia Logoteta1, Stefania Ferro1, Laura De Luca1, Nunzio Iraci1, Christophe Pannecouque2, Annamaria Monforte1
		1University, Messina, Italy; 2Katholieke Universiteit, Leuven, Belgium; 3Istituto Di Genetica Molecolare IGM-CNR, Pavia, Italy
	129.	The Application of Phosphoramidate Protide Technology to Acyclovir Confers Novel Anti-HIV Inhibition
		Marco Derudas1, Christopher Mcguigan1, Andrea Brancale1, Leonid Margolis2, Jan Balzarini3
		1Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; 2Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States; 3Rega Institute For Medical Research, Leuven, Belgium
	130.	Design, Synthesis, and Biological Evaluation of Novel Fluoro Derivatives of BCNA
		Marco Derudas1, Maurizio Quintiliani1, Christopher Mcguigan1, Andrea Brancale1, Geoffrey Henson2, Jan Balzarini3
		1Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; 2Inibitex Inc., Alpharetta, GA, United States; 3Rega Institute For Medical Research, Leuven, Belgium
	131.	4,4-Disubstituted Cyclohexylamine based CCR5 Chemokine Receptor Antagonists as Anti-HIV-1 Agents
		Maosheng Duan, Wieslaw Kazmierski, Christopher Aquino, Rob Ferris, Terry Kenakin, Chris Watson, Pat Wheelan
		Infectious Disease Center For Excellence In Drug Discovery, Glaxosmithkline, Research Triangle Park, NC, United States
	132.	Macrocyclic Polyamines Targeting the Cellular HIV Co-Receptors, CXCR4 and CCR5.
		Sunil Hamal1, Li Cui1, Bell Thomas1, Aquaro Stefano2, Dana Huskens3, Dominique Schols3
		1Department of Chemistry, University of Nevada, Reno, NV, United States; 2Department of Experimental Medicine and Biochemical Sciences, University of Rome ‘Tor Vergata’, Rome, Italy; 3Rega Institute For Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
	133.	Synthesis and Antiviral Activity of Substituted Uracils
		Alexander Ivanov1, Vera Tunitskaya1, Olga Smirnova1, Robert W. Buckheit, Jr.2, Katherine Seley-Radtke3, Alexander Ozerov4, Mikhail Novikov4
		1Engelhardt Institute of Molecular Biology, Moscow, Russia; 2University of Maryland, Baltimore County, Baltimore, MD, United States; 3imquest Biosciences, Inc., Frederick, MD, United States; 4Volgograd State Medical University, Volgograd, Russia
	134.	Synthesis and Biological Evaluation of Acyclic Nucleotide Analogues of Bicyclic Pyrimidine Bases
		Zlatko Janeba1, Antonín Holý1, Robert Snoeck2, Graciela Andrei2, Eric De Clercq2, Jan Balzarini2
		1Institute of Organic Chemistry and Biochemistry AS CR, Prague, Czech Republic; 2Rega Institute For Medical Research, Leuven, Belgium
	135.	HIV-1 Gag Matrix Protein Fragments and Polyacid Conjugates Designed for the HIV Inhibition
		E. Karaseva, A. Serbin, I. Rodionov, A. Vasiliev, V. Abramov, O. Alikhanova
		Health RDF, Moscow, Russia
	136.	CXCR4 Antagonists: A New Generation of Configurationally Restricted Bis-Azamacrocyclic Compounds
		Abid Khan1, Gary Nicholson1, Graeme Mcrobbie1, John Greenman4, Christophe Pannecouque2, Dirk Daelemans2, Dominique Schols2, Erik De Clercq2, Timothy J. Hubin3, Stephen J. Archibald1
		1Department of Chemistry, University of Hull, Hull, United Kingdom; 2Rega Institute For Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium; 3Department of Chemistry and Physics, Southwestern Oklahoma State University, Weatherford, OK, United States; 4Centre For Medical Research, University of Hull, Hull, United Kingdom
	137.	West Nile Virus Helicase: Homology Modeling and Docking Studies
		Mohammed Khedr, Andrea Brancale
		Cardiff University, Welsh School of Pharmacy, Cardiff, United Kingdom
	138.	Nucleoside Phosphonate Analogues Modified by Lipophilic Cage Moiety as Potential Antiviral Agents.
		Yuri Klimochkin1, Marina Leonova1, Alexander Reznikov1, Andrey Shiraev1, Eugene Golovin1, Eugene Belanov2
		1Samara State Technical University, Samara, Russia; 2FSRI SRC “Vector”, Novosibirsk, Russia
	139.	Antiviral Activity of New Derivatives of CAGE Compounds
		Yuri Klimochkin1, Vitalij Osyanin1, Pavel Krasnikov1, Marina Leonova1, Eugene Golovin1, Sergey Balakhnin2, Eugene Belanov2
		1Samara State Technical University, Samara, Russia; 2FSRI SRC “Vector”, Novosibirsk, Russia
	140.	Antiviral Activity of Tetrahydro-2(1H)-Pyrimidinones and Related Compounds: Classification SAR Study
		V. Kuz’min1, E. Muratov1,2, A. Artemenko1, D. Sidzhakova3, A. Galabov3
		1A.V. Bogatsky Physical-Chemical Institute NASU, Odessa, Ukraine; 2University of Nort Carolina, Chapel Hill, NC, USA; 3S. Angeloff Institute of Microbiology BAS, Sofia, Bulgaria
	141.	Cyclosaligenyl-Di-D4TMP: Highly Loaded Cyclosal-Pronucleotides that Release Two Equivalents of Nucleotides and Leaving One Masking Unit
		Chris Meier1, Nicolas Gisch1, Ducho Christian1, Balzarini Jan2
		1Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany; 2Rega Institute For Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
	142.	Computer-aided Drug Design of Novel Anti-Coxsackievirus B3 Nancy Agents By Means of HIT QSAR
		E. Muratov1, E. Varlamova1, V. Kuz’min1, A. Artemenko1, A. Kuz’mina2, A. Tropsha3, V. Makarov4, O. Riabova4, P. Wutzler5, M. Schmidtke5
		1A.V. Bogatsky Physical-Chemical Institute NASU, Odessa, Ukraine; 2I.I. Mechnikov Odessa National Medical University, Odessa, Ukraine; 3University of North Carolina, Chapel Hill, NC, USA; 4Research Center For Antibiotics, Moscow, Russia; 5Institute of Virology and Antiviral Therapy, F. Schiller University, Jena, Germany
	143.	A Heterocyclic Molecule with Significant Activity against Dengue Virus
		Vasu Nair1, Guochen Chi1, Qingning Shu1, Justin Julander2, Donald Smee2
		1University of Georgia, Athens, GA, USA; 2Utah State University, Logan, UT, USA
	144.	Synthesis and Properties of Cyclosal-phosphatetriesters of Fluorescent Bicyclic Nucleoside Analogues (BCNAS)
		Florian Pertenbreiter, Chris Meier
		Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany
	145.	Anti-H5N1 Influenza Virus Activity of Carbocyclic Cytosine Nucleosides
		J.R. Rao1, A.K. Jha1, A. Sharon1, C.W. Day2, D.L. Bernard2, D.F. Smee2, C.K. Chu1
		1University of Georgia, College of Pharmacy, Athens, GA, USA; 2Utah State University Institute For Antiviral Research, Logan, UT, USA
	146.	Synthesis of CADA Analog Pro-drugs Designed as Novel Down-Modulators of the CD4 Receptor
		Emily Scarbrough1, Sreenivasa Anugu1, Kurt Vermeire2, Dominique Schols2, Thomas Bell1
		1Department of Chemistry, University of Nevada, Reno, NV, USA; 2Rega Institute For Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
	147.	Bioreversible Protection of Nucleosidediphosphates—Synthesis and Properties
		Tilmann Schulz1, Henning J. Jessen1, Jan Balzarini2, Chris Meier1
		1Institue of Organic Chemistry, Department of Chemistry, Faculty of Science, University of Hamburg, Martin-Luther-King Platz 6, D-20146, Hamburg, Germany; 2Rega Institute For Medical Research, Katholieke Universiteit Leuven, Minderbroederstraat 10, B-3000, Leuven, Belgium
	148.	Multivalent Synthetic Lectin Polymers against HIV
		Julie Jay1, Bonnie Lai2, Patrick Kiser1
		1University of Utah, Department of Bioengineering, Salt Lake City, UT, USA; 2Duke University, Department of Biomedical Engineering, Durham, NC, USA
	149.	Induction of HIV-1 Gene Expression in Human Monocytic Cells by the Failed Microbicide Carrageenan Occurs through Activation of Toll-like Receptor 4 (TLR4)
		Shawn Keogan, Vanessa Pirrone, Shendra Passic, Brian Wigdahl, Fred Krebs
		Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA
	150.	Sevi and Semen Impair the Anti-HIV-1 Activity of Drugs and Microbicides
		Kim Kyeong-Ae1, Shibo Jiang2, Frank Kirchhoff1, Jan Muench1
		1Institiute of Virology, Ulm, Germany; 2New York Blood Center, New York, NY, USA
	151.	Nonoxynol-9 (N-9), After Repeated Applications, Does Not Result in Cumulative Damage to the Murine Cervicovaginal Epithelium
		Karissa Lozenski1, Tina Kish-Catalone2, Brian Wigdahl1, Fred Krebs1
		1Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA; 2Department of Natural Sciences, Desales University, Center Valley, PA, USA
	152.	Resistance Developed against Alamethicin an Antimicrobial Peptide in Enterococcus faecalis is Directly Proportional to its Concentration
		Jitender Mehla, S.K., Sood
		National Dairy Research Institute, Karnal, India
	153.	Using the CONRAD Testing Algorithm to Evaluate the Cytotoxicity and Anti-HIV-1 Activity of Candidate Microbicide Compounds
		Shendra Passic1, Vanessa Pirrone1, Brian Wigdahl1, Gustavo Doncel2, Fred Krebs1
		1Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA; 2CONRAD, Arlington, VA, USA
	154.	Clinical Failures of Select Polyanionic Microbicide Candidates may be Predicted by In Vitro Enhancement of HIV-1 Infection
		Vanessa Pirrone, Shendra Passic, Brian Wigdahl, Fred Krebs
		Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA
	155.	A Macromolecular Basis for Microbicides Dual Protecting against HIV and Cytomegalovirus Infection
		A. Serbin1, E. Karaseva1, Y. Egorov1, I. Dunaeva1, M. Pavlova2, A. Kushch2
		1Biomodulators RC, Health RDF, Moscow, Russia; 2D.I. Ivanovski Res. Inst. of Virology, RAMS, Moscow, Russia
	156.	CADA—A Potential Anti-HIV Microbicide that Specifically Targets the Cellular CD4 Receptor
		Kurt Vermeire1, Thomas Bell2, Roger Le Grand3, Joachim Brouwers4, Patrick Augustijns4, Dominique Schols1
		1Rega Institute For Medical Research, K.U. Leuven, Leuven, Belgium; 2Department of Chemistry, University of Nevada, Reno, NV, USA; 3Service De Neurovirologie, Fontenay-Aux-Roses, France; 4Laboratory For Pharmacotechnology and Biopharmacy, K.U. Leuven, Leuven, Belgium
	157.	The Development of HIV-1 NCp7 Inhibitors as Components in Combination Topical Microbicides
		Karen Watson, Kathleen Powers, Lu Yang, Tracy Hartman, Robert W. Buckheit, Jr.
		ImQuest BioSciences, Inc., Frederick, MD, USA
	158.	Development of a Long Lasting Combination Microbicide Product Consisting of Highly Potent Compounds Exhibiting Multiple Mechanisms of Action
		Karen Watson, Lu Yang, Kathleen Powers, Joseph Kurczewski, Tracy Hartman, Robert Buckheit, Jr.
		ImQuest BioSciences, Inc., Frederick, MD, USA
Wednesday, May 6, 2009
Prusoff Young Investigator Award Lecture
Mediterranean East
	159.	Presentation of Award
		Amy Patick, Ph.D.
		President, ISAR
	160.	Viral Kinases as Targets for Antiviral Therapy
		Mark Prichard, Ph.D.
		University of Alabama School of Medicine, Birmingham, AL, USA
Oral Session 4: Herpesviruses And Poxviruses
Chairs: Rhonda Cardin, Ph.D. and Mark Prichard, Ph.D.
Mediterranean East
08:45–11:30
08:45	161.	Inhibition of Herpesvirus Replication with 5-Iodo-4′-Thio-2′-Deoxyuridine
		Mark Prichard1, Debra Quenelle1, Caroll Hartline1, Emma Harden1, Geraldine Jefferson1, Samuel Frederick1, Terri Rice1, Deborah Collins1, Kamal Tiwari2, Joseph Maddry2, Richard Whitley1, John Secrist2, Earl Kern1
		1University of Alabama School of Medicine, Birmingham, AL, USA; 2Southern Research Institute, Birmingham, AL, USA
09:00	162.	Selection and Characterization of (S)-1-[3-Hydroxy-2-(Phosphonomethoxypropyl)-2,6-Diaminopurine [HPMPDAP] Resistant Camelpox Viruses
		Sophie Duraffour1, Robert Snoeck1, Pierre Fiten2, Ghislain Opdenakker2, Graciela Andrei1
		1Laboratory of Virology, Rega Institute, Leuven, Belgium; 2Laboratory of Immunobiology, Rega Institute, Leuven, Belgium
09:15	163.	Effects of Anti-Human Papillomavirus (HPV) Disease Agents on HPV Episome Levels In Vitro: Cidofovir, Podophyllotoxin, and Pyrrole-imidazole Polyamides
		Terri Edwards1, Kevin Koeller2, James Bashkin1,2, Chris Fisher1
		1Nanovir, Kalamazoo, MI, USA; 2University of Missouri-St. Louis, St. Louis, MO, USA
09:30		Break
09:50	164.	Invitation to the 23rd ICAR, San Francisco, CA, USA
		Chris McGuigan, Ph.D.
		Chair, ICAR Conference Committee
10:00		ISAR Business Meeting
10:15	165.	Identification of the Type of Cells Responsible for Transfer of Herpes Simplex Virus (HSV) and Vaccinia Virus (VACV) Infection to Epithelial Cells Grown in 3D
		Graciela Andrei1, Dirk Daelemans1, Els Vanstreels1, Sophie Duraffour1, Joos Van Den Oord2, Erik De Clercq1, Robert Snoeck1
		1Rega Institute For Medical Research, K.U. Leuven, Leuven, Belgium; 2Laboratory of Morphology and Molecular Pathology, K.U. Leuven, Leuven, Belgium
10:30	166.	Drug Resistance Mutations in HSV-1 UL5 Selected Using a Helicase-Primase Inhibitor: Frequency and Effects on Virus Growth and Pathogenicity
		Subhajit Biswas, Soumi Sukla, Hugh J Field
		Department of Veterinary Medicine, University of Cambridge, Cambridge, CB3 0ES, United Kingdom
10:45	167.	Murine Model of Recurrent Vaginal HSV-2 Shedding and Effect of Acyclovir
		Rhonda Cardin, Nicholas Farley, Fernando Bravo, Julie Earwood, Nancy Sawtell, David Bernstein
		Cincinnati Children's Hosp, Med. Center, Cincinnati, OH, USA
11:00	168.	Activation of Cyclopropavir Involves Unique Phosphorylation by Guanylate Kinase
		Brian G. Gentry1, Chengwei Li2, John C. Drach1, Jiri Zemlicka2
		1University of Michigan, Ann Arbor, MI, USA; 2Wayne State University, Detroit, MI, USA
11:15	169.	EBNA1—A Virally Encoded Protein Binds Cellular Host Promoters in a Unique Sequence and Directly Interferes with Cellular Gene Expression: Implications for Genomics Approaches in Drug Design
		Allon Canaan, Vincent Schulz, Milind Mahajan, Alexander Urban, Sherman Weissman
		Yale University School of Medicine, New Haven, CT, USA
Oral Session 5: Respiratory Viruses, Emerging Viruses And Biodefense
Chairs: Dale Barnhard, Ph.D. and Brian Gowen, Ph.D.
Mediterranean East
13:00–16:00
13:00	170.	Plenary: Filoviral Minigenome Systems and iVLPs as Tools for Antiviral Research
		Stephan Becker, Ph.D.
		University of Marburg, Marburg, Germany
13:30	171.	Identification and Mechanistic Studies on a Novel Class of Influenza Virus Fusion Inhibitors
		Evelien Vanderlinden1, Nesrin Cesur2, Zafer Cesur2, Fusun Goktas2, Mathy Froeyen1, Charles Russell3, Lieve Naesens1
		1Rega Institute For Medical Research, Leuven, Belgium; 2Istanbul University, Faculty of Pharmacy, Istanbul, Turkey; 3St. Jude Children's Research Hospital, Memphis, TN, USA
13:45	172.	Novel Broad-spectrum Biopharmaceuticals: From HIV-1 to Pandemic Influenza a Virus
		François Jean1, Vesna Posarac1, Peter Cheung2, Martine Boutin1, Heather Braybrook1, Richard Harrigan2
		1Department of Microbiology & Immunology, University of British Columbia, Vancouver, BC, Canada; 2B.C. Centre For Excellence In HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada
14:00	173.	Recruitment of the TSG101/ESCRT-I Machinery in Host Cells by Influenza Virus: Implications for Broad Spectrum Therapy
		Leyla Diaz, Josephine Cassella, Aurelio Bonavia, Roxanne Duan, David Santos, Zena Fesseha, Michael Goldblatt, Michael Kinch
		Functional Genetics, Inc., Gaithersburg, MD, USA
14:15	174.	Role of Na Mutations Conferring Resistance to NA Inhibitors on Viral Fitness and Pathogenicity in A/Turkey/15/06 (H5N1) Influenza Virus
		Natalia A. Ilyushina, Jon P. Seiler, Robert G. Webster, Elena A. Govorkova
		St. Jude Children's Research Hospital, Memphis, TN, USA
14:30	175.	In-Vivo Efficacy Evaluation of Vaccines against H5N1 Influenza Virus
		Nutan Mytle
		Southern Research Institute, Birmingham, AL, USA
14:45	176.	Activity of Certain 5-Substituted-4′-Thio Pyrimindine Nucleosides against Orthopoxvirus Infections
		Earl Kern1, Mark Prichard1, Debra Quenelle1, Kathy Keith1, Kamal Tiwari2, Joseph Maddry2, John Secrist III2
		1University of Alabama School of Medicine, Birmingham, AL, USA; 2Southern Research Institute, Birmingham, AL, USA
15:00	177.	Motor Unit Number Estimation as a Therapeutic Marker in Acute and Persistent West Nile Virus Infection In Hamsters
		John D. Morrey1, Venkatraman Siddharthan1, Hong Wang1, Neil E. Motter1, Jeffery O. Hall1, Robert D. Skinner2, Ramona T. Skirpstunas1
		1Utah State University, Logan, UT, USA; 2University of Arkansas For Medical Sciences, Little Rock, AR, USA
15:15	178.	Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity against Dengue Virus
		Jinhong Chang1, Lijuan Wang1, Dongling Ma1, Xiaodong Xu2,3, Wouter Schul4, Pei-Yong Shi4, Peter M. Mason5, Nigel Bourne5, Robert Moriarty6, Ju-Tao Guo1, Timothy M. Block1,2
		1Drexel University College of Medicine, Doylestown, PA, USA; 2Institute For Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, PA, USA; 3Pharmabridge Inc., Doylestown, PA, USA; 4Novartis Institute For Tropical Diseases, Chromos, Singapore; 5University of Texas Medical Branch, Galveston, TX, USA; 6University of Illinois, Chicago, IL, USA
15:30	179.	Using The C57BL/6 and SKH1 Strains to Evaluate the Efficacy of CMX001 following Lethal Respiratory Infections with Ectromelia Virus
		Scott Parker1, Christina Oberle1, Ed Hembrador1, Jill Schriewer1, Geroge Painter2, Randall Lanier2
		1Saint Louis University, St Louis, MO, USA; 2Chimerix Inc., Durham, NC, USA
15:45	180.	Novel 9-Arylpurines, as Selective Inhibitors of In Vitro Enterovirus Replication
		Hendrik Jan Thibaut1, Leire Aguado2, Lonneke Van Der Linden3, Armando De Palma1, María-José Camarasa2, Jan Balzarini1, Frank Van Kuppeveld3, María Jesús Pérez-Pérez2, Johan Neyts1
		1Rega Institute For Medical Research, Kuleuven, Leuven, Belgium; 2Instituto De Química Médica (CSIC), Madrid, Spain; 3Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen Centre For Molecular Life Sciences, Nijmegen, Netherlands
Shotgun Poster Presentations
Chairs: Robert W. Buckheit, Jr., Ph.D. and Chris McGuigan, Ph.D.
Mediterranean East
16:15–18:15
Thursday, May 7, 2009
Oral Session 6: Mini-Symposium: Perspectives And Challenges In The Development Of Topical Microbicides
Chairs: Sharon Hillier, Ph.D. and Jim Turpin, Ph.D.
Mediterranean East
08:00–10:00
08:00	181.	A Microbicide Perspective: Past, Present, and Future
		Sharon Hillier, Ph.D.
		University of Pittsburgh, Pittsburgh, PA, USA
08:20	182.	Microbicide Product Development: What is a Microbicide?
		Jim Turpin
		DAIDS, NIAID, NIH, Bethesda, MD, USA
08:40	183.	Formulation of Compounds for Vaginal and Rectal Delivery
		Patrick Kiser, Ph.D.
		University of Utah, Salt Lake City, UT, USA
09:00	184.	Development of Microbicides with Broad Based Anti-infective Action
		Betsy Herold, M.D.
		The Albert Einstein University, Bronx, NY, USA
09:20	185.	The Microbicide Pipeline: Clinical Development Success and Failure
		Joseph Romano, Ph.D.
		International Partnership For Microbicides, Silver Spring, MD, USA
09:40		Break
Oral Session 7: Microbicides, Drug Design And Late Breaker Presentations
Chairs: Nick Kaludov, Ph.D. and Andrea Brancale, Ph.D.
Mediterranean East
10:00 a.m.–12:00
10:00	186.	Design of an Intravaginal Ring for Simultaneous Delivery of Antiretroviral Drugs
		Todd Johnson, Kavita Gupta, Patrick Kiser
		University of Utah, Department of Bioengineering, Salt Lake City, UT, USA
10:15	187.	Biophysical Mechanisms in Microbicide Pharmacokinetics
		David Katz, Marcus Henderson, Bonnie Lai, Anthony Geonnotti, Jennifer Peters
		Department of Biomedical Engineering, Duke University, Durham, NC, USA
10:30	188.	Virtual Reality Applications in Antiviral Drug Design
		Nicola Zonta, Andrea Brancale
		Welsh School of Pharmacy, Cardiff, United Kingdom
10:45	189.	Identification of a Small-Molecule Antiviral with Broad-spectrum Application to Multiple, Lethal Virus Types
		Abdul Yunus1, Travis Warren2, Kelly Warfield3, Sven Enterlein3, Shaojing Chang1, Hanwen Mao1, Javad Aman3, Sina Bavari2, Michael Goldblatt1, Michael Kinch1
		1Functional Genetics, Inc., Gaithersburg, MD, USA; 2United States Army Medical Research Instiute of Infectious Diseases, Fort Detrick, MD, USA; 3Integrated Biotherapeutics, Germantown, MD, USA
11:00		Late Breaker Presentation
11:15		Late Breaker Presentation
11:30		Late Breaker Presentation
11:45		Late Breaker Presentation